8-K: NEXGEL Spins Off Drug Delivery Program to NexGelRx

NEXGEL announced the spin-off of its drug delivery program into NexGelRx, securing a 5% perpetual royalty and a 19.99% non-dilutive equity stake.

Summary

• NEXGEL, Inc. has spun off select drug delivery application assets into a new entity, NexGelRx, which will focus exclusively on developing and commercializing prescription (Rx) drug delivery solutions using NEXGEL's proprietary hydrogel technology.
• At the time of the spin-off, NexGelRx secured initial funding from outside investors.
• Under the license agreement, NEXGEL will receive a 5% royalty in perpetuity for the global rights to its technology for Rx drug delivery by NexGelRx.
• NEXGEL will retain a 19.99% equity stake in NexGelRx, which is non-dilutive for up to $8 million of capital investment into NexGelRx.
• NEXGEL will also serve as the exclusive manufacturer of hydrogel for NexGelRx.

Sentiment

Score: 8

Explanation: The filing indicates a highly positive strategic move for NEXGEL. The spin-off allows the company to unlock value from its drug delivery program without direct funding, secure a perpetual royalty, maintain a significant non-dilutive equity stake, and gain an exclusive manufacturing contract. This de-risks the parent company while creating a new avenue for growth and potential shareholder returns.

Positives

• NEXGEL retains a significant 19.99% non-dilutive equity stake in NexGelRx, allowing participation in future growth without further capital outlay for this portion.
• A perpetual 5% global royalty on all products sold by NexGelRx using NEXGEL's technology provides a long-term, recurring revenue stream.
• The spin-off allows NEXGEL to de-risk its balance sheet by having NexGelRx pursue high-value Rx opportunities with external funding, rather than NEXGEL funding the development itself.
• NEXGEL secures an exclusive manufacturing agreement for hydrogel for NexGelRx, ensuring continued revenue and utilization of its manufacturing capabilities.
• The transaction enables NEXGEL to focus on its core contract manufacturing and consumer branded products in the health and beauty space, streamlining its business strategy.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from anticipated results.
• The Company's actual results, performance, or achievements could be materially different from any anticipated results due to various reasons.
• Additional risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, under 'Risk Factors'.

Future Outlook

NexGelRx is expected to focus on pursuing high-value prescription (Rx) opportunities, potentially leading to new topical and systemic therapies. NEXGEL will continue to focus on contract manufacturing and consumer branded products in the health and beauty space, while also seeking further opportunities to unlock shareholder value. The electron beam generated hydrogel technology is anticipated to become a platform for a family of useful and transformative therapies.

Management Comments

• Adam Levy, CEO of NEXGEL, stated, "This spin-off provides potential return on investment for our shareholders through a dedicated team and platform to pursue high-value Rx opportunities while NEXGEL remains focused on contract manufacturing and consumer branded products in the health and beauty space."
• Adam Levy also commented, "This transaction enables NEXGEL to pursue what we believe to be a potentially large opportunity without NEXGEL itself having to fund its development."
• Dr. Jerome Zeldis, a director of NEXGEL and NexGelRx, expressed, "The electron beam generated hydrogel lends itself to creating new topical and systemic therapies that can supplement existing therapies or create new ways to treat patients in a variety of clinical areas."
• Dr. Jerome Zeldis further noted, "The focus of using the hydrogel for drug delivery could lead to it becoming a platform for a family of useful and transformative therapies."

Industry Context

The spin-off strategy is a common approach in the pharmaceutical and biotech industries, allowing companies to create specialized entities to focus on specific drug development programs. This often enables the new entity to attract dedicated capital and management expertise, while the parent company can streamline its operations and focus on its core business segments. This move positions NexGelRx to compete in the specialized Rx drug delivery market, leveraging NEXGEL's proprietary hydrogel technology.

Related Party Transactions

• NEXGEL entered into a license agreement with NexGelRx, granting global rights to its technology for Rx drug delivery in exchange for a 5% perpetual royalty.
• NEXGEL will be the exclusive manufacturer of hydrogel for NexGelRx.
• Dr. Jerome Zeldis, a director of NEXGEL, will also serve as a director of NexGelRx.

Stakeholder Impact

• Shareholders: Potential for increased value through NEXGEL's non-dilutive equity stake and perpetual royalty from NexGelRx, while NEXGEL's core business focuses on profitability.
• Employees: Potential for increased focus within NEXGEL on contract manufacturing and consumer products, and new opportunities within NexGelRx for drug delivery specialization.
• Customers: NEXGEL's existing customers for healthcare, beauty, and OTC products will continue to be served, while NexGelRx will develop new Rx drug delivery solutions for the pharmaceutical market.

Next Steps

• NexGelRx will focus on developing and commercializing prescription (Rx) drug delivery solutions.
• NEXGEL will continue to focus on contract manufacturing and consumer branded products in the health and beauty space.
• NEXGEL will pursue further opportunities to unlock value for its shareholders.

Key Dates

Recommendation

The spin-off is a strategically sound move that de-risks NEXGEL's balance sheet by offloading the funding requirements for high-value Rx development to external investors. NEXGEL retains significant upside through a 19.99% non-dilutive equity stake and a perpetual 5% global royalty, alongside an exclusive manufacturing agreement. This structure allows NEXGEL to benefit from the potential success of NexGelRx without incurring direct development costs, while also sharpening its focus on its profitable core businesses. This transaction is likely to unlock significant long-term value for shareholders.

Keywords

NEXGEL, NXGL, NexGelRx, spin-off, drug delivery, hydrogel, pharmaceutical, biotech, healthcare, medical device, royalty, equity stake, contract manufacturing, OTC products, prescription drugs